Tommasin, Silvia http://orcid.org/0000-0001-9088-7968
De Giglio, Laura http://orcid.org/0000-0001-9018-7320
Ruggieri, Serena http://orcid.org/0000-0001-5287-3290
Petsas, Nikolaos http://orcid.org/0000-0001-7150-9697
Giannì, Costanza http://orcid.org/0000-0002-4018-169X
Pozzilli, Carlo http://orcid.org/0000-0002-6360-4798
Pantano, Patrizia http://orcid.org/0000-0001-9659-8294
Funding for this research was provided by:
Fondazione Italiana Sclerosi Multipla (2018/S/3)
Article History
Received: 13 November 2019
Accepted: 27 February 2020
First Online: 18 March 2020
Compliance with ethical standards
:
: ST and CG declare no conflict of interest. LDG received speaking honoraria from Genzyme and Novartis; travel grants from Biogen, Merk, and Teva; and consulting fees from Genzyme, Merk, and Novartis. SR received fees as speaking honoraria from Teva, Merck Serono, and Biogen; travel grants from Biogen and Merck Serono; and fees as advisory board consultant from Merck Serono and Novartis. NP received speaker fees from Biogen and mission support from Genzyme and Novartis. CP received consulting and lecture fees and research funding and travel grants from Almirall, Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva. PP received founding for travel from Novartis, Genzyme, Bracco, and Biogen.
: All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.